Predicted survival of women with breast cancer is no longer based solely on the results of RCTs stratified by age and menopausal status, but also based on breast cancer genomic variability and on the status of certain breast cancer receptors, namely the ER, the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). The gene discussed is ERBB2; the disease is cancer.